Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tarrex Biopharma, a US-China Startup, Approved to Start US Cancer Drug Trial

publication date: Mar 21, 2017
Tarrex Biopharma, a San Diego-Xiamen biopharma, reported that the US FDA approved its Investigational New Drug (IND) application for TX803, a novel treatment for colorectal cancer. Tarrex licensed global rights to TX803 and related IP from the Sanford Burnham Prebys Medical Discovery Institute in San Diego. Privately owned Tarrex has an office in San Diego and a research facility in Xiamen. Xiaokun Zhang, PhD, Cofounder and Chief Scientific Advisor to Tarrex, is Dean of the School of Pharmaceutical Sciences at Xiamen University and Professor at Sanford-Burnham. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital